Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$338.91 USD
+26.80 (8.59%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $335.58 -3.33 (-0.98%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MDGL 338.91 +26.80(8.59%)
Will MDGL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDGL
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates
Other News for MDGL
Madrigal Pharmaceuticals (MDGL) Reports Strong Q2 Revenue Boost
Madrigal Pharmaceuticals reports Q2 EPS ($1.90), consensus ($3.53)
Madrigal Pharmaceuticals, Inc. GAAP EPS of -$1.90 beats by $1.51, revenue of $212.8M beats by $50.63M
Madrigal Pharmaceuticals Inc (MDGL) Reports Strong Q2 2025 Financial Results and Strategic ...